

PSYCHOPHARMACOLOGY NEWSLETTER AND SUBSTANCE ABUSE

Volume 25, Number 2

Division 28 - The American Psychological Association

Summer, 1992

PRESIDENT'S LETTER

Ronald W. Wood
President, Division 28

This issue brings you the Centennial Convention program events of interest to the Division. The Division has risen to the occasion, and we thank you all for making it such a success. We are particularly indebted to Nancy Ator for her superb efforts as program chair. See you in Washington!

As you peruse this issue (see p. 7), you will also discover an offer we could not refuse, an opportunity to subscribe to *Psychopharmacology (Berlin)* at an affordable rate, if the Division administers the U.S. subscription process. This newsletter offer is the only opportunity you will have this year at this price, so send in your money promptly.

The new APA journal *Experimental and Clinical Psychopharmacology* is progressing nicely under the leadership of its editor, Bob Schuster (see p. 2). This venture shows every sign of being a successful enterprise, and we look forward to it eagerly. Read, contribute, and subscribe!

I have four additional newsworthy items to share:

1) The Division has recommended that APA (and APS) nominate Robert L. Balster for the Directorship of the National Institute on Drug Abuse. We used a multiphase process consisting of three solicitations of suggestions from the 15% of our membership subscribing to DIV28@GWUVM; discussions with senior psychopharmacologists, probing their willingness to serve and their suggested nominees; a report to the Executive Board; and a vote of the Executive Committee. Dr. Balster has earned the respect of the Division, and it was a pleasure to suggest his nomination to APA's chief executive officer, Ray Fowler.

2) ADAMHA, the saga. Having survived horsetrading of various sorts only to encounter opposition to needle exchange research programs, block grant allocation formu-

las, and the provision of methadone to patients in the absence of other services, the reorganization seems at this writing to be overcoming its final hurdles. One would expect the three institutes to move to NIH and the service components to comprise a successor agency, SAMHSA. The reorganization would not occur until October 1, at the earliest. The White House is actively interviewing candidates for the directorship, and Joe Matarazzo, a past-APA president and scientist, a worthy and viable prospective director, has been interviewed several times at this writing. We wish him well, and ADAMHA/SAMHSA would do well under his leadership.

3) Dr. Kenneth Olden, the new Director of the National Institute of Environmental Health Sciences, was awarded an APA presidential citation at the recent Board on Scientific Affairs meeting. The Division, in conjunction with Policy and Science Directorate staff, briefed the Board in advance of the award. Dr. Olden is leading the NIEHS in new directions, and environmentally-induced behavioral disorders and nervous system injuries are emerging as growth areas in the agency's portfolio. Dr. Olden has agreed to address our annual meeting next year, and we look forward to this continuing relationship with pleasant anticipation.

4) The Saving Lives Coalition met on Capitol Hill, and Bill Woolverton and I represented the Division and APA at this event. Elizabeth Baldwin of the Science Directorate played a major role in the planning and successful execution of this event, which brought together representatives of a number of professional associations and patient groups for a news briefing, awards ceremony, and reception recognizing the importance to public health of biomedical research using laboratory animals. I found this to be an extraordinarily moving event, and you will be reassured to know that we have active support for our research efforts from Drs. Sullivan, Healy, Novello, Diggs, Johnson, Goodwin, Gordis, and other Federal officials. Several days later I received a card and a family photograph expressing thanks to me for pursuing biomedical research. It was signed by each member of the family, and I was deeply touched by this gesture. We are

cont. on p. 5

IN BRIEF

Kenneth A. Perkins
Chair, Public Information

Note: The Public Information Committee is charged with increasing awareness and accurate understanding of psychopharmacology and substance abuse research among other psychologists, scientists from other fields, and the general public. With the change in the Division's name and the broadening of its focus, it is important to keep members of the Division familiar with the diversity of psychological research relevant to psychopharmacology and substance abuse. The goal of this column is to provide concise descriptions of selected recent human and animal studies exploring a variety of topics of potential interest to members. This inaugural column describes a recent study examining expectancy of caffeine's effects on motor performance.

It is widely recognized that responses to drugs may be influenced by factors other than their pharmacological actions, including expectations based on previous experience or explicit instructions from others. Expectancy effects have been observed on subjective and social responses to drug intake. Expectancy effects on behavioral performance responses, however, have seldom been clearly demonstrated—an important gap in this literature since such performance effects may be critical in reinforcing drug self-administration. In a recent issue of *Psychopharmacology* (1992, 106:209-214), Fillmore and Vogel-Sprott of the University of Waterloo described a study in which they manipulated the expectations of human volunteers regarding the effects of caffeine ingestion on motor performance. Following baseline training on a computerized pursuit rotor task, 3 groups ($n = 14$ each) of young male moderate caffeine users were explicitly told they would receive caffeinated coffee and then engage in further trials of the task. One group was told that their performance would be impaired by caffeine and another that their performance would be enhanced by caffeine; the third was given no information on the expected effects of caffeine on task performance. Although each subject believed he received caffeinated coffee, in actuality all three groups received decaffeinated coffee. A fourth, control group received no beverage. The group expecting performance enhancement showed the greatest improvement in task performance, and the group expecting performance impairment showed the poorest task performance; performance of the group receiving no information and of the control group given no beverage fell between that of the other groups. This finding indicates that differential drug effects on performance may be predicted based on the expected effects. These results may also have implications for research studies examining performance effects of drugs that do not assess and/or control for subject expectations of drug effects.

APA LAUNCHES NEW JOURNAL

Charles R. Schuster

I am pleased to confirm the rumor that APA is sponsoring a new journal entitled *Experimental and Clinical Psychopharmacology* and that I have accepted the challenge of being the first editor. I am extremely honored to have been asked to take on this position and excited about the role this journal can have in advancing the field of psychopharmacology.

When I was asked by the APA to consider becoming the editor, I responded concerning my views about the scope of the new journal: "Let me be more specific about the kinds of research that I believe should be given priority for publication in this journal. In the basic research area, priority should be given to articles that stress the integration of data across levels of analysis of pharmacologic action—from molecular biology to neurochemistry, to electrophysiology of brain systems, and finally to mood and behavior. The rapidly emerging techniques of brain dialysis and voltometry, which allow the simultaneous measurement of neurochemical and behavioral events in animals, are examples of the ways in which such integration can be approached. Similarly, the imaging techniques of PET and NMR, as well as the increasingly sophisticated measurement of brain activity through EEG and MEG, allow simultaneous measurement of drug-induced changes in brain activity, mood, cognition, and behavior. Such studies have the potential to advance our knowledge about the actions of the drugs under study as well as about the biological correlates of behavior."

There are many other areas in which psychologists are uniquely suited to make important contributions to psychopharmacology—e.g., the analysis of factors such as behavioral history and personality that may account for individual differences in the effects of psychoactive drugs on mood and behavior. The way that the context or current environmental circumstances in which drugs are taken modifies their effects is another issue of major clinical and theoretical significance. The continued analysis of the role of learning and conditioning in the development of sensitization and tolerance to the effects of repeatedly administered drugs is of fundamental importance. These are but a few of the areas of basic psychopharmacologic research that should be of interest to psychologists and that the journal should feature.

In the clinical area, I believe that the journal should give a high priority to studies that not only investigate the effectiveness of a medication for the treatment of a specific disorder but also determine how the medication interacts with other forms of behavioral and psychosocial interventions. I would not like to see the journal filled with traditional "drug

cont. on p. 7

1992 APA PROGRAM SCHEDULE: DIVISION 28

2101

FRIDAY, AUGUST 14

9:00-10:50 am (WASHINGTON HILTON: Monroe West) **Symposium: Neurobehavioral Toxicology of Learning and Memory: Environmental Determinants.** 1. The Nature of Lead-Induced Learning Impairments and Neurotransmitter System Involvement (Deborah Cory-Slechta). 2. Cold Stress-Induced Changes in Behavior: Alterations in Catecholamines and Neuropeptides (John Thomas). 3. Neurobehavioral Toxicology of Cholinesterase-Inhibiting Pesticides (Robert Macphail). 4. Cross-species Extrapolation in the Assessment of Neurotoxicity (David Eckerman). Discussant (Peter Dews). Chair: John Glowa. [Co-sponsored by Div. 6]

10:00-11:50 am (WASHINGTON HILTON: Military) **Symposium: Childhood/Familial Characteristics and Alcohol/Substance Abuse: Risk and Etiology.** 1. Multiple Processes in Transmission of Risk from Parent to Child (Robert Zucker). 2. Objective Measurement of Behavioral Activity in Sons of Substance Abusers. (Ralph Tarter). 3. Parental Alcohol Problems and Externalizing Disorders of Childhood: Laboratory Studies (Alan Lang). 4. Familial Influences on Adolescent Substance Abuse (Michael Windle). Discussant (William Felham). Chair: William Felham.

11:00-11:50 am (WASHINGTON HILTON: International Ballroom West) **Science Weekend: Stress and Health: Human and Animal Approaches; Invited Address: NIH Initiatives on Minority and Women's Health Research (Bernadine Healey).** Chair: Neil Schneiderman. [Science Directorate, Div. 38]

12:00

11:00-11:50 am (WASHINGTON HILTON: Jefferson West) **Invited Address: Social Stress: Neurochemical Consequences and Pharmacological Protection (Klaus Miczek).** Chair: Alice Young. **NOTE:** The official program is wrong; this is the correct time!

12:00-12:50 pm (WASHINGTON HILTON: Jefferson East) **Invited Address: Childhood Lead Toxicity; The Interaction of Industry, Government and Science (Herbert Needleman).** Discussant (Bernard Weiss). Chair: Ronald Wood.

1:00-2:50 pm (WASHINGTON HILTON: Lincoln East) **Symposium: Behavior Analysis and Drug Abuse Policy.** 1. Implications of Behavior Analysis for Drug Abuse Policy (Charles R. Schuster). 2. Behavioral Economics and Drug Abuse Policy (Steven Hursh). 3. Policy Makers' View of Substance Abuse Treatment: Why is it so Grim? (Herbert Kleber). Discussant (Bruce Carnes). Chair: Steven Hursh. [Co-sponsored by Div. 25]

3:00-4:50 pm (WASHINGTON HILTON: Cabinet) **Centennial Event, Symposium: Present at the Creation of Division 28.** 1. 1st President (Murray Jarvik). 2. 2nd President (Victor Laties). 3. 5th President (Bernard Weiss). 4. 6th President (Leonard Cook). 5. 11th President (Joseph Brady). 6. Distinguished Affiliate (Peter Dews). Chair: Herbert Barry, III, 12th President.

5:15-6:45 pm (NATIONAL ZOO, 3000 block of Connecticut Ave. NW) **Social Hour** [Co-sponsored by Div. 3, 6, 25, & 38]. 5:15-6:00 pm (Bird House) Refreshments; 6:15-6:45 (Education Bldg.) Zoo researchers present current animal research projects.

SATURDAY, AUGUST 15

8:00-8:50 am (WASHINGTON HILTON: Georgetown East) **Paper Session: Clinical Issues in Substance Abuse Treatment.** 1) Counseling Effectiveness and Information Processing in Adult Children of Alcoholics (Nanci Jensen, Steven Schandler, Nancyann Cervantes). 2) Alcoholism Risk, Alcohol Use, and Spinal Cord Injury (Steven Schandler, Michael Cohen, Julia Cavin-Stice, Michael Mardis, Sherry Rascoe Frank). 3) Behavioral Approaches to Assuring Compliance with Tuberculosis-Treatment Regimen in Methadone-Maintained Patients (Ronith Elk). 4) Cumulative versus Stabilizing Effects of Methadone Maintenance (Keiko Powers, Douglas Anglin). Chair: Carolyn Mazure.

9:00-10:50 am (WASHINGTON HILTON: Conservatory) **Paper Session: Psychopharmacology.** 1. Chronic and Acute Tolerance to Subjective Effects of Nicotine (Kenneth Perkins, James Grobe, Leonard Epstein, Anthony Caggiola, Richard Stiller, & Jennifer Goettler). 2. Time-sense and Subjective Intoxication: A New Balanced Placebo Design (William Lapp, Lorraine Collins, William Zywiak, & Charles Izzo). 3. Maximizing Predictive Power of Alcohol Expectancies Using Multimethod Assessment (Bruce Rather, Jack Darkes, Paul Greenbaum, & Mark Goldman). 4. Effects of Ethanol on Cooperative Responding (Ralph Spiga). 5. Behavioral Effects of Caffeine and CGS 15943, a Novel Adenosine Antagonist (Leonard Howell & Larry Byrd). 6. Rearing Environment Influences Rats' Sensitivity to Cocaine and Amphetamine (Stephen Fowler, Julie Johnson, & Mary Kallman). 7. The Opioid-Stress Interaction: Examination of the Role of Conditioning (Yavin Shaham). Chair: John Glowa.

11:00-11:50 am (WASHINGTON HILTON: State) **Invited Addresses: Young Psychopharmacologist Awards.** 1. Human Behavioral Pharmacology and Abuse Potential of Anxiolytic Drugs (Suzette Evans). 2. Central Neuropeptide Effects on Primate Behavior: Influence of Social Context (James Winslow). Chair: Larry Byrd.

1:00-1:50 pm (WASHINGTON HILTON: Cabinet) **Invited Address: Smoking Research: The Last 25 Years (Murray Jarvik).** Chair: Jack Henningfield.

2:00-3:50 pm (WASHINGTON HILTON: Military) **Symposium: Behavioral Factors in Drug Sensitization and Tolerance.** 1. Conditioned Sensitization to Cocaine: Pharmacological and Neuroanatomical Substrates (Susan Weiss). 2. Behavioral and Pharmacological Factors Influencing Enhanced Sensitivity to Opioid Antagonists (Charles Schindler). 3. Compensatory Learning in Ethanol Tolerance and its Subsequent "Hedonic" Valence (David Gauvin). 4. Behavioral Factors Involved in Contingent Tolerance to Benzodiazepines (Christine

Sannerud). Discussant (James Smith). Chairs: Christine Sannerud & Charles Schindler.

3:00-3:50 pm (WASHINGTON HILTON: Lincoln West) Science Directorate Invited Address: Theriomancy to Flagellomania: Basic and Applied Research on Drug Taking and Self-Injury (Travis Thompson). Chair: Larry Byrd.

3:00-4:50 pm (OMNI SHOREHAM: Ambassador) Ethnic Minority Miniconvention Symposium: Interethnic Psychopharmacology: Current Pharmacogenetic, Pharmacokinetic and Diagnostic Considerations. 1. Tricyclic Antidepressants and RBC/Plasma Lithium Differences in Black Americans (Tony Strickland). 2. Ethnicity and Psychopharmacology: The Asian Perspective (Keh-Ming Lin). 3. Sociocologic Issues in Psychopharmacology: A Methodologic Critique (Samuel M. Turner). 4. Cultural Factors in Pharmacotherapy (William Lawson). Discussant (Matthew Rudorfer). Chair: Tony Strickland. [Co-sponsored by Div 12, Sect VI]

5:00-5:50 pm (SHERATON WASHINGTON: North Cotillion) Div. 40 Conversation Hour: Prescription Privileges: Issues for the Clinical Neuropsychologist (Robert Balster).

5:00-6:50 pm (WASHINGTON HILTON: Exhibit Hall) Poster Session and Social Hour (cash bar) 1. Knowledge Mapping: Psychoeducational Tool in Relapse Prevention Training for Probationers (Kevin Knight, Dwayne Simpson, & Donald Dansereau). 2. Individual Assessment Profile (IAP): Standardizing the Assessment of Substance Abusers (Patrick Flynn, Robert Hubbard, Douglas Fountain, Timothy Smith, & Jeffrey Hoffman). 3. Characteristics of Methadone Patients Responding to Take-Home Incentives (Michael Kidorf & Maxine Stitzer). 4. Effects of Drug Pretreatment on Behavioral Disruptions of Drug Withdrawal (Joshua Rodefer & Marilyn Carroll). 5. A Comparative Analysis of Cocaine Abuse Treatment Strategies (Jeffrey Hoffman & Barry Caudill, Robert Hubbard, & Patrick Flynn). 6. Utility of the MCMI-II in Assessing Cocaine Abuse Treatment (Johnie Hamilton, Jr., Patrick Flynn, Jeffrey Hoffman, & Barry Caudill). 7. Description of Clients in Four Modalities of Drug Abuse Treatment (Gail Woods, Robert Hubbard, Kathleen Jordan, & Patrick Flynn). 8. Alcohol/Drug Use Patterns in Four Modalities of Drug Abuse Treatment (Gail Woods, Patrick Flynn, & Robert Hubbard). 9. Alcohol and Drug Abusers Entering Treatment: How Different Are They? (Peter Scraganjan, Thomas Brown, & Jacques Tremblay). 10. Impact of Contextual Variables on Adolescent Substance Use (Jeffrey Ashby). 11. Introversion-Extraversion and Situational Preference for Stimulants and Depressants (Richard Lewis & William Goggin). 12. Situational Influences on Cues Used to Judge Intoxication (Janice Williams & Jeffrey Burroughs). 13. Role of Intoxicated Practice in Behavioral Alcohol Tolerance in Humans (Robert Bennett, Don Cherek, John Roache, & Ralph Spiga). 14. Drug Involvement Among Alcoholic Men: Relationships to Psychopathology and Adaptation (Fernando Gonzalez, Robert Zucker, & Hiram Fitzgerald). 15. Activating and Disinhibiting Effects of Alcohol at Low Dosages (Pamela Valley & John Salamone). 16. WAIS-R Differentiation of Alcoholic Cognitive Impairment Syn-

drome From Alcohol-Induced Dementia (William Canter & Christine Sannerud). 17. Alcohol Effects Reported by Impulsive and Nonimpulsive Individuals (Carolyn Morse & Vincent Adesso). 18. Alcohol Effects on Selective Attention for Threat in Anxiety-Sensitive Females (Sherry Stewart, Marie Achille, Isabelle Dubois-Nguyen, & Robert Fihl). 19. Lactate-Induced Panic Attacks in Alcoholics with Panic Disorder (Teresa Lindquist, David George, & Markku Linnoila). 20. Alcohol, Frontal Lobe Functioning and Aggression (Mark Lau, Robert Fihl, & Jordan Peterson). 21. Prenatal Opiate Receptor Blockade: Changes in Postnatal Behavior and Development (Nancy Shepanek, Robert Smith, Linda Anderson, Catherine Medici, & Shannon Dodson). 22. Physical/Neurobehavioral Development of Rhesus Neonates Exposed Prenatally to Cocaine (Jane Ellis, Leonard Howell & Larry Byrd). 23. Characterizing Prenatal Growth and Development in Rhesus Monkeys Using Ultrasonography (Jane Ellis & Larry Byrd). 24. Opioid Receptor Subtypes Mediate Opposing Behaviors Through Their Dopamine Interaction (Karen Ward & Priscilla Kehoe). 25. The Influence of Buprenorphine on the EEG of Heroin Addicts (Bonnie Koeppl, Peter Koeppl, & Ronald Herning). 26. Depression Secondary to Decongestant Medication (Benzion Twerski). 27. Does Unrestricted Benzodiazepine Availability Lead to Widespread Use? (Miren Busto, I. Ruiz, A. Gacitua, C. Roco, F. Espinoza, & U. Busto). 28. The Effects of Oxazepam on Anxiety in a Nonclinical Population (Jennifer Landon & Kenneth Sher). 29. Anxiety and Drinking Behavior: Moderating Effects of Alcohol-Related Expectancies (Matt Kushner & Kenneth Sher). 30. Implicit Priming of an Alcohol Expectancy Memory Network (Genevieve Chenier & Mark Goldman). 31. Priming the Pump: Alcohol Expectancy Activation Increases Drinking Behavior (Laurie Roehrich & Mark Goldman). 32. Effect of Minimum Drinking Age on Alcohol Consumption and Impairment (Vincent Adesso, Eric Devine, Constantine Ioannidis, & Bertrand Berger). 33. Gender and Age Effects on Alcohol Expectancies (Leslie Lundahl, Tania Davis, Vincent Adesso, Bertrand Berger, & Celeste Milligan). 34. Defeat and Threat of Attack Occasion Pentylentetrazole-appropriate Responding (Jeffrey Vivian, E.M. Weerts, & Klaus Miczek). 35. Repeated Administration of PCP and Amphetamine: Effects on Social Behavior (Rhea Steinpreis, J. Sokolowski, A. Papanikolaou, & J. Salamone). 36. Strain-Dependent Effects in Behavioral Pharmacology (John Glowa). 37. Opioid Sensitivity as Measured by Operant Schedule-Controlled Responding (Gregory Elmer, J. Pieper, Steven Goldberg, & Frank George). 38. Nicotine Increases Pre-pulse Inhibition of Acoustic Startle Reflex in Rats (Jane Acri, David Morse, & Neil Grunberg). 39. Consumption of Concurrently Available Money and Cigarettes: Response Requirement Effects (Richard DeGrandpre, Warren Bickel, Stephen Higgins, & John Hughes). 40. Cigarette and Affective Cue Reactivity Effects in Female Smokers (Paul Leonard & Thomas Lombardo). PLUS 46 add'l posters from co-sponsoring Divs. 3, 6, 25.

SUNDAY, AUGUST 16

8:00-9:50 am (SHERATON WASHINGTON: Richmond Room) Science/Practice Weekend. Symposium: Pharmacological Adjuncts in Alcoholism Treatment. 1. Receptor Mediation of the

Subjective Effects of Ethanol (Kathleen Grant). 2. Buspirone as an Adjunct to Relapse Prevention in Anxious Alcoholics (Henry Krantzler). 3. Naltrexone and Coping Skills Therapy for Alcohol Dependence (Stephanie O'Malley). 4. Pharmacotherapy and Relapse Prevention Counseling with Alcoholics (Helen Annis). 5. Disulfiram Treatment of Alcoholism: Past, Present and Future (Richard Fuller). Discussant (John Allen). Chair: Maxine Stitzer [Co-sponsored by Div 12, 16, 18, 28, 40, 41]

9:00-9:50 am (WASHINGTON HILTON: Cabinet) New Fellow's Address: Prenatal Cocaine Exposure Alters Offspring's Neurobehavioral Function: Animal Model Studies (Linda Spear). [Co-sponsored by Div 6, 28]

10:00-10:50 am (WASHINGTON HILTON: Lincoln West) New Fellow's Invited Address: Stimulus Equivalence and Drug Dependence: Findings and Implications (Warren Bickel). Chair: Marilyn Carroll.

11:00-11:50 am (WASHINGTON HILTON: Lincoln West) New Fellow's Invited Address: Gender and Stress: Important Variables in Basic Substance Abuse Research (Neil Grunberg). Chair: Harriet deWit. [Co-sponsored by Div 38, 28]

1:00-1:50 pm (WASHINGTON HILTON: Jefferson East) APA Event. 1991 Distinguished Scientific Applications of Psychology Awardee Address: Labor of Love: The Applied Operant (Joseph Brady). Chair: James Barrett.

1:00-2:50 pm (WASHINGTON HILTON: Thoroughbred) Symposium: Washington, D.C. Metropolitan Area Drug Study (DC*MADS): Initial Findings. 1. The Washington, D. C. Metropolitan Area Drug Study: Overview and Challenges (Elizabeth Lambert). 2. (Drug Use and Related Problems Among Household Residents (Robert Bray). 3. Drug Use Among Residents of Institutions (Gregory Gaertner). 4. Drug Use and the Severity of Homelessness (Michael Dennis). Discussant (Pamela Fischer). Chair: Robert Bray.

2:00-2:50 pm (WASHINGTON HILTON: Monroe East) Invited Address: Health and Behavior: New Directions for NIMH (Frederick Goodwin). Chair: Frederick King. [Co-sponsored by Science Directorate, Div 6, 28]

MONDAY, AUGUST 17

9:00-10:50 am (WASHINGTON HILTON: Georgetown East) Symposium: Contemporary Research in Behavioral Pharmacology. 1. Drugs as Discriminative Stimuli (Nancy Aizer). 2. Behavioral Models in Drug Discovery (James Barrett). 3. Animal Models of Drug Self-administration (Marilyn Carroll). 4. Advances in Understanding the Neural Basis of Drugs' Behavioral Effects (Steven Dworkin). Discussant (Michael Perone). Chair: Mark Galizio. [Co-Sponsored by Div 25]

11:00-12:50 pm (WASHINGTON HILTON: Georgetown West) Symposium: Relationship of Problem Severity to Treatment Outcome in

Cocaine Dependence. 1. Fluoxetine Dose, Visit Frequency, and Severity in Cocaine Dependence Treatment (John Grabowski). 2. Treating Alcoholic Cocaine Users with Disulfiram and Naltrexone (Kathleen Carroll). 3. Drug Cue Reactivity as a Possible "Severity" Dimension in Cocaine Dependence (Anna Rose Childress). 4. A Behavioral Approach to Outpatient Treatment of Cocaine Dependence (Stephen Higgins). Discussant (George Bigelow). Chairs: John Grabowski & Stephen Higgins.

1:00-1:50 pm (WASHINGTON HILTON, Lincoln West) Invited Address: Animal Research versus Medical Progress (Adrian Morrison). Chair: Larry Byrd.

2:00-3:50 pm (WASHINGTON HILTON: Military) Symposium: Assessment and Treatment Outcome Evaluation of Substance Abusers. 1. D.C. Initiative Treatment Outcome Assessment Battery (Jeffrey Hoffman). 2. Drug Abuse Treatment for AIDS-Risks Reduction (DATAR) Assessment Battery (Dwayne Simpson). 3. Yale Substance Abuse Treatment Unit Psychotherapy Research Battery (Kathleen Carroll). 4. Assessment and Treatment Outcome Evaluation: The CATOR Approach (Norman Hoffman). Chair: Barry Brown.

4:00-4:50 pm (WASHINGTON HILTON: Map) Presidential Address: Basic Research and the Protection of Public Health (Ronald Wood). Chair: Klaus Miczek.

5:00-5:50 pm (WASHINGTON HILTON: Map) Div. 28 Business Meeting. Chair: Ronald Wood.

TUESDAY, AUGUST 18

11:00-12:50 pm (SHERATON WASHINGTON: Arlington Room) Div. 38 event--Symposium: From Substance Lapse to Relapse: Theory, Data, and Intervention Options. From Lapse to Relapse: The Role of Drug Stimulus Priming (Maxine Stitzer). [Co-Listed by Div 28]

PRESIDENT'S LETTER (cont.)

in the business of saving lives and improving the human condition, and we have appreciative families and organizations behind us. Bill, Liz, and I made a point of visiting several offices to encourage the prompt release of Rep. Stenholm's bill from the Judiciary committee, where it is undergoing scrutiny of provisions unrelated to the protection of research facilities. Having already passed the Senate, and having achieved 261 sponsors in the House, the likelihood of its becoming law in this session is excellent.

To subscribe to the Division's electronic mail discussion list, send the one line message: SUB DIV28 firstname lastname. to LISTSERV@GWUVM. If you encounter difficulties, you may ask for help from Cheri Fullerton of the Science Directorate, APASDCF@GWUVM.

OPEN POSITIONS

NRSA Postdoctoral Fellowship: NIDA-sponsored position, under direction of M. Douglas Anglin, Ph.D., provides drug abuse knowledge, sound research techniques, practical research experience, and exposure to a variety of drug abuse settings and methods. Opportunity to select specific area of focus for independent and supervised research in epidemiology, etiology, treatment process/outcome, pharmacotherapy, and social policy issues. Requires completion of Ph.D. in a social science. US citizens or permanent residents only. Stipends in accordance with NRSA/NIDA levels based upon level of training; health insurance provided. Submit application letter with outline of research experience and interests, desire for drug abuse research career, specific area of research, and focused problem within area; CV; transcripts; and 3 letters of recommendation (major advisor & 2 others familiar with scholastic and research background) to Edna Owens, Administrator, UCLA Drug Abuse Research Center, 1100 Glendon Ave., Suite 763, Los Angeles, CA 90024, (310) 825-9057. UCLA is an EO/AA Employer.

Postdoctoral Research Training in Behavioral Pharmacology: Postdoctoral traineeship beginning Spring/Summer, 1993. Areas of research include the effects of psychoactive drugs on learning and memory; behavioral measures of opioid dependence and withdrawal; discriminative stimulus effects of drugs of abuse; behavioral effects of novel analgesics; drugs of abuse, dependence and immune function; and in vivo applications of receptor theory. Opioids, benzodiazepines, barbiturates, stimulants, as well as excitatory amino acid agonists and antagonists are evaluated in primates, pigeons and rodents using a variety of behavioral and biochemical techniques. Candidates should have completed (or nearly completed) Ph.D. in pharmacology, neuroscience, physiological psychology or related field. Initial appointment is for 2 years, renewable; salary competitive, commensurate with experience. Send letter of interest, CV, and 3 letters of recommendation to Charles P. France, Ph.D. (504-942-8382; FAX 942-8383), Dept. of Pharmacology, LA State Univ. Medical Center, 1100 Florida Ave., New Orleans, LA 70119. LA State Univ. is an EO/AA Employer.

Research Scientists: 6 Research Scientists with established credentials in treatment research required for the following research areas: Cognitive Behavioral Intervention, Youth and Family Clinical Research, Behavioral Pharmacology, Comorbidity and Behavioural Risk Factors, Treatment Systems Research, and Pharmacotherapy. Working within one of these areas, the incumbent will develop, conduct, and disseminate research findings, including preparation of research proposals for internal/external grant review; participate in training and, where appropriate, clinical care in a research context; present papers at scientific/professional meetings; engage in teaching activities and, if qualified, supervise graduate and postdoctoral research trainees; assume administrative responsibility for research projects. The incumbent will be required to demonstrate excellence, originality, innovation and leadership in research, willing partnership in CRTI teams, and openness to research collaboration inside/outside the organization. Qualifications: M.D. and Fellowship in the Royal College of Physicians and Surgeons of Canada or equivalent, or Ph.D. in behavioral, biomedical, or social sciences; registered or registration-eligible in the Province of Ontario, where appropriate; specific research qualifications as evidenced by M.Sc., Ph.D., and/or completion of a recognized postdoctoral research training and

research experience; eligibility for, or holding University appointment at minimum rank of Asst. Professor. Cross-appointments with Univ. of Toronto possible. Forward CV and letter of application by 10/1/92 to: Ms. Joanne Cohen, Research Administrator, Addiction Research Foundation, 33 Russell St., Toronto, Ontario M5S 2S1, (416) 595-6000, ext. 7651.

Clinical Psychologists: Two Clinical Psychologists with strong research abilities are required in the following areas: Cognitive Behavioral Intervention and Comorbidity and Behavioral Risk Factors. Working within one of these areas, the incumbent will provide psychological services (assessment, treatment, and consultation) in support of the CRTI's research and clinical service needs; provide clinical supervision and participate (as co-investigator) in research development and publication, and preparation of research grants; assist in developing and disseminating promising clinical procedures; engage in teaching and other professional activities. Qualifications: Ph.D. in Clinical Psychology or related behavioral science; registered or registration-eligible in Ontario, where appropriate; listed or eligible for listing in the Canadian Register of Health Service Providers; demonstrated clinical experience and strong research abilities. Experience in the assessment and treatment of substance-use disorders desirable. Cross-appointments may be arranged at the Univ. of Toronto. Salary and benefits commensurate with experience and qualifications. Preference given to those eligible to work in Canada. Send CV and letter of application by 10/1/92 to Ms. Joanne Cohen, Research Administrator, Addiction Research Foundation, 33 Russell St., Toronto, Ontario M5S 2S1, (416) 595-6000, ext. 7651.

Postdoctoral Research Fellowships: National Research Service Awards are available at the Alcohol and Drug Abuse Research Center, McLean Hospital (an affiliate of Harvard Medical School and Massachusetts General Hospital), in a multidisciplinary research program that includes basic, clinical, and treatment research. Trainees may participate in research on the behavioral pharmacology of substance abuse; the neuroendocrine consequences of cocaine and alcohol abuse; the effects of drug abuse on the brain as assessed by brain imaging techniques (MRI, MRS, SPECT, and EEG) and the evaluation of the safety and effectiveness of new pharmacotherapies for the treatment of drug abuse. The clinical research programs emphasize analysis of the antecedents and consequences of drug abuse by women. The Ph.D., M.D., or M.D./Ph.D. is required. Salary commensurate with experience (PGY 1-7). Send CV, reprints of some recent papers, a brief statement about your research interests and goals, and the names of 3 references (including complete address and telephone number) to Dr. Jack H. Mendelson, Prof. of Psychiatry (Neuroscience) or Dr. Nancy K. Mello, Prof. of Psychology (Neuroscience), Co-Directors, Alcohol and Drug Abuse Research Center, McLean Hospital, 115 Mill St., Belmont, MA 02178. McLean Hospital is an equal opportunity/Affirmative Action Employer.

SCHUSTER RECEIVES AWARD

Charles R. Schuster, Ph.D. has been selected as the recipient of the Distinguished Scientific Award for the Applications of Psychology for 1992. A ceremony and reception honoring all APA award recipients is scheduled to take place at the August, 1993 APA convention in Toronto.

NEW APA JOURNAL (cont.)

house* reports of new pharmacologic agents for the treatment of anxiety, panic disorder, OCD, etc. Further, the journal should give high priority to clinical studies that expand the outcome indicators of effectiveness to include measures of the quality of life and the impact of the medication on the clients' family and work interactions.

The impact of therapeutic medications, drugs of abuse, and environmental chemical toxins on human development across the entire life cycle from conception to death is a very important area and one in which psychologists can make unique contributions. An understanding of the biological, behavioral, and psychosocial stages of human development is essential to an understanding of their interaction with pharmacological agents. Further, our rapidly expanding older population has presented us with a variety of behavioral, cognitive, and affective problems that may be caused or exacerbated by chemical toxins and drugs of abuse or attenuated by therapeutic medications. These are areas that should be of interest to a wide audience of psychologists.

Although reports of original research should be the major emphasis, I believe that a few select (usually solicited) review articles should also be included in some issues.

Further, to give the journal some "zest", I would recommend that selected commentaries on articles be allowed. Again, in the main, these commentaries would be solicited.

If this journal is to be a success, I will need the help and support of all Division 28 members. Please do not hesitate to write to me with your ideas as to how the journal can be maximally useful. We are going to publish the first issue in September, 1993, which hopefully will be a double issue of 3-400 pages. If you have any top quality manuscripts that you would like to have considered for publication in the "premier" issue, send them off to me as soon as possible. I am currently recruiting editorial board members; when this task is completed, we will publish the names in the Newsletter. I am attempting to be broad in coverage in this selection process so that experimental and clinical psychopharmacologists and toxicologists will be represented.

I am very excited about the opportunities afforded by a journal devoted to "psychological" aspects of psychopharmacology. I hope you share my enthusiasm and will send manuscripts and be willing to serve as reviewers. Together we can make this journal a great success. Please forward all correspondence regarding this new APA journal to Charles R. Schuster, 5353 Strathmore Avenue, Kensington, Maryland 20895.

DIVISION 28 OFFICERS:

| | <i>Term</i> | <i>Newsletter Editor</i> | <i>Cynthia S. Pomerleau</i> | <i>8/91-8/94</i> |
|-------------------------------|--|--------------------------|---|--|
| <i>Elected:</i> | | | (313) 764-7152 | |
| President | Ronald W. Wood (914) 351-4249 wood@mvax.med.nyu.edu | 8/90-8/93 | usergeds@umichum | |
| | | Membership Chair | Warren Bickel (802) 660-3067 m_coahran@uvmvax.uvm.edu | 8/91-8/94 |
| President-Elect | Maxine Sitzer (410) 550-0042 msitzer@bpeu.uucp.jhu.edu | 8/91-8/94 | CPDD Liaison | Roy Pickens (301) 443-6697 |
| | | Past-President | Public Information | Ken A. Perkins (412) 624-1716 |
| | Klaus Miczek (617) 381-3414 kmiczek@tufts | 8/89-8/92 | ASPET Liaison Officers | Alice M. Young (313) 577-3290 userghd6@waynemts |
| Council Representative | Stephen C. Fowler (601) 232-7383 pymbb@umsvm | 2/91-1/94 | APA Public Affairs Liaison | George E. Bigelow (410) 550-0035 |
| | | Members-at-large | APS Liaison | Donald Overton (215) 787-1534 |
| | Robert Sprague (217) 333-4123 | 8/89-8/92 | | 8/91-8/92 |
| | Marilyn E. Carroll (612) 626-6289 | 8/90-8/93 | Committee on Nominations | Larry D. Byrd (404) 727-7730 peggy@rmy.emory.edu |
| | Alice M. Young (313) 577-3290 userghd6@waynemts | 9/91-8/94 | Neurobehavioral Tox. Committee | Robert L. Balster (804) 786-8402 balster@vouvax |
| <i>Appointed:</i> | | | | 8/91-8/93 |
| Treasurer | Jack E. Henningfield (410) 550-1494 | 8/91-8/94 | Committee on Animal Research | Hugh L. Evans (914) 351-4249 evans@nyumed |
| | | | | 8/91-8/92 |
| Secretary | Stephen T. Higgins (802) 660-3066 s_higgins@uvmvax.uvm.edu | 8/91-8/93 | Committee on Prescript. Priv. | Marlyne Kilbey (313) 577-2802 |
| | | | | 8/91-8/94 |